In 2018, we assembled the best scientists in different specialties and developed the first DNA test for personalized medical cannabis guidance. Then we worked with Illumina and Tempus to help develop a custom beadechip microarray with specific markers to identify and analyze endocannabinoid system DNA. In early 2023, Endocanna Health was awarded a patent for our novel EndoDNA™ test. Today, our patented test is used Internationally, including at major universities engaged in cannabinoid research, where we are involved in clinical trials and peer-reviewed studies. Every DNA report we offer includes multiple peer-reviewed references.
In 2021, we co-published our first research paper where we identified a genetic link to Cannabis Hyperemesis Syndrome or CHS.